Independent Presentations by Clinical Leaders Underscore Stereotaxis System's Utility in Peripheral and Interventional Cardiology

ST. LOUIS, Oct. 10 /PRNewswire-FirstCall/ -- Stereotaxis, Inc. (Nasdaq: STXS) today announced that its presence at Transcatheter Cardiovascular Therapeutics (TCT) 2008 will reflect advancements being made with its Magnetic Navigation System for interventional cardiology applications, as well as the broadening utility of the system for peripheral interventions. In particular, the company and several independent presentations will highlight the value of its RF PowerAssert(TM) Magnetic Guidewire in the magnetic vascular lab.

Cleared by the U.S. Food and Drug Administration in August 2008, the RF PowerAssert Magnetic Guidewire is the only magnetically enabled device capable of intra-lesion steering that is available for crossing peripheral occlusions, including CTOs. Used with the Niobe Magnetic Navigation System, it is the only technology that enables precise intra-lesion control over its distal tip.

"In addition to its proven value in the EP lab, the Niobe System is a broad platform for all manner of interventional procedures, particularly for coronary and peripheral applications," said Bevil J. Hogg, Stereotaxis CEO. "To date, the Niobe Magnetic Navigation System has been used to perform thousands of percutaneous coronary interventions. Indeed, several independent presentations at TCT will cast light on advancements with the Niobe System in these areas."

At TCT, Dr. William Gray of New York Presbyterian / Columbia University Medical Center in New York City will present a CTO treatment performed with the RF PowerAssert Magnetic Guidewire during the Cath lab of the Future session in Room 151AB at 10:30am, Monday, October 13th.

Dr. Mark Patterson of Onze Lieve Vrouwe Gathuis hospital in Amsterdam will give a presentation during the same session titled "Stereotaxis Magnetic Assisted Coronary Interventions: Experiences and Conclusions after Treating Almost 1,000 Patients."

Dr. John Lasala of Washington University Barnes-Jewish Hospital will also present in Innovative and Futuristic Concepts, Room 145B addressing "Multifunctional Utility of the Stereotaxis Magnetic Guidance System: Applications for EP, Cell Therapy, Structural Heart Disease, and Coronary/Peripheral Atherosclerosis.

And Dr. Richard Bach from Washington University Barnes-Jewish Hospital will present an electronic poster titled "Evaluation of a Magnetically Navigated Radiofrequency Guidewire for Recanalization of Experimentally Created Total Peripheral Vascular Occlusions in a Porcine Model." His poster will appear in TCT Abstracts, TCT-608.

Against this backdrop of broadening clinical utility, Stereotaxis plans to highlight the simplicity, safety, and efficacy that are enabled by its magnetic navigation and information management systems in Booth No. 874. In addition to the RF PowerAssert Magnetic Guidewire, the Company plans to showcase these additional technologies for the magnetic vascular lab.

    --  The Odyssey Total Information Solution connects the growing installed
        base of EP and vascular labs, within and between hospitals. 
        Odyssey's consolidated workstation allows physicians to view and
        control critical patient data from a single screen. In addition, Odyssey
        includes powerful archiving capability, Odyssey Cinema(TM), that allows
        clinicians to store and replay procedures or segments of procedures,
        real time in high definition, thereby providing them with a significant
        new tool for clinical collaboration, remote consultation, and training.
    --  Navigant 3.0 Software is the next generation software for Niobe focused
        on simplification, automation, and enhanced integration. Navigant
        3.0's capabilities include enhanced 3D vessel reconstruction and
        improved CT integration. When used in combination with Odyssey,
        Stereotaxis believes that Navigant 3.0 will significantly advance cath
        lab productivity and procedural workflow efficiency.
    --  The Full Family of Stereotaxis Guidewires has the ability to navigate
        tortuous anatomy and deliver appropriate therapy.

TCT 2008 will be held from October 12 - 17, 2008, at the Washington Convention Center in Washington D.C. It is the largest annual gathering of interventionalists in the world.

For more information about Stereotaxis' presence at TCT 2008 or its magnetic vascular lab technologies, visit www.stereotaxis.com.

About Stereotaxis

Stereotaxis designs, manufactures and markets an advanced cardiology instrument control system for use in a hospital's interventional surgical suite to enhance the treatment of coronary artery disease and arrhythmias. The Stereotaxis System is designed to enable physicians to complete more complex interventional procedures by providing image guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. This is achieved using computer-controlled, externally applied magnetic fields that govern the motion of the working tip of the catheter or guidewire, resulting in improved navigation, shorter procedure time and reduced x-ray exposure. The core components of the Stereotaxis system have received regulatory clearance in the U.S., Europe and Canada.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe," "estimate," "project," "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance for the Company's products in the marketplace, competitive factors, changes in government reimbursement procedures, dependence upon third-party vendors, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.

SOURCE Stereotaxis, Inc.